{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:07:00Z","timestamp":1777378020352,"version":"3.51.4"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","funder":[{"name":"Ministry of Science and Technology of China, National Key R&D Program of China","award":["2016YFC1306800"],"award-info":[{"award-number":["2016YFC1306800"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81671329"],"award-info":[{"award-number":["81671329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81671332"],"award-info":[{"award-number":["81671332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81901832"],"award-info":[{"award-number":["81901832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Key Laboratory of Psychotic Disorders","award":["13dz2260500"],"award-info":[{"award-number":["13dz2260500"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["No.2018SHZDZX01"],"award-info":[{"award-number":["No.2018SHZDZX01"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19ZR1477800"],"award-info":[{"award-number":["19ZR1477800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19ZR1445200"],"award-info":[{"award-number":["19ZR1445200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19441907800"],"award-info":[{"award-number":["19441907800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["17411953100"],"award-info":[{"award-number":["17411953100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19410710800"],"award-info":[{"award-number":["19410710800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19411969100"],"award-info":[{"award-number":["19411969100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["20ZR1448600"],"award-info":[{"award-number":["20ZR1448600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["20ZR1448600"],"award-info":[{"award-number":["20ZR1448600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019330","name":"Shanghai Clinical Research Center for Mental Health","doi-asserted-by":"crossref","award":["19MC1911100"],"award-info":[{"award-number":["19MC1911100"]}],"id":[{"id":"10.13039\/501100019330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Center at Shanghai Mental Health Center","award":["CRC2018ZD01"],"award-info":[{"award-number":["CRC2018ZD01"]}]},{"name":"Clinical Research Center at Shanghai Mental Health Center","award":["CRC2018ZD04"],"award-info":[{"award-number":["CRC2018ZD04"]}]},{"name":"Clinical Research Center at Shanghai Mental Health Center","award":["CRC2018YB01"],"award-info":[{"award-number":["CRC2018YB01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction In a previous report, we used canonical correlation analysis to classify individuals with clinical high risk (CHR) of psychosis into the 3 subtypes: subtype-1, characterized by extensive negative symptoms and cognitive deficits, appeared to have the highest risk for conversion to psychosis; subtype-2, characterized by thought and behavioral disorganization, with moderate cognitive impairment; subtype-3, characterized by the mildest symptoms and cognitive deficits. The present study attempted to identify these subtypes\u2019 response to antipsychotic (AP) treatment.<\/jats:p><jats:p>\nMethods A total of 289 individuals with CHR were identified and followed up for 2 years. Individuals with CHR were classified by subtype. Use of APs was examined at 2-month, 1-year, and 2-year follow-up interviews that inquired after the subjects\u2019 medication history since the first visit. The main outcome was remission, determined according to global assessment of function (GAF) score (i.\u2009e., functional outcome) and SIPS positive symptom score (symptomatic outcome) at the follow-up points.<\/jats:p><jats:p>\nResults Among the 289 individuals with CHR included in the current analysis, 223 (77.2%) were treated using APs for at least 2 weeks during the follow-up period. Individuals with CHR tended to show significant improvement in both symptoms and function after 2 years, but subtypes exhibited significantly different trajectories. Subtype status can predict AP treatment outcome in terms of remission. The likelihood of remission differed significantly among the subtype groups. The remission rates for individuals with subtypes 1\u20133 treated using AP were 13.5%, 36.1%, and 67.0%, respectively.<\/jats:p><jats:p>\nDiscussion These subtypes may be of clinical value in AP treatment decision-making in the CHR population.<\/jats:p>","DOI":"10.1055\/a-1252-2942","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T22:53:36Z","timestamp":1602543216000},"page":"23-30","source":"Crossref","is-referenced-by-count":13,"title":["Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission"],"prefix":"10.1055","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-7119","authenticated-orcid":false,"given":"TianHong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JunJie","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiHua","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YanYan","family":"Wei","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoChen","family":"Tang","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YeGang","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiRu","family":"Cui","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YingYing","family":"Tang","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hui","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChunBo","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiJun","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai"},{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai"},{"name":"Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1176\/appi.ajp.159.5.863","article-title":"Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity","volume":"159","author":"T J Miller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/S0007125000297602","article-title":"Prediction of psychosis. A step towards indicated prevention of schizophrenia","volume":"172","author":"A R Yung","year":"1998","journal-title":"Br J Psychiatry Supplement"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-244X-14-97","article-title":"Psychotic symptoms, functioning and coping in adolescents with mental illness","volume":"14","author":"J T Wigman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/eip.12386","article-title":"A study on negative and depressive symptom prevalence in individuals at ultra-high risk for psychosis","volume":"12","author":"M Azar","year":"2018","journal-title":"Early Interv Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.schres.2017.08.020","article-title":"Progressive decline of cognition during the conversion from prodrome to psychosis with a characteristic pattern of the theory of mind compensated by neurocognition","volume":"195","author":"T Zhang","year":"2018","journal-title":"Schizophr Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2015.11.026","article-title":"Declining transition rates to psychotic disorder in \u201cultra-high risk\u201d clients: Investigation of a dilution effect","volume":"170","author":"J A Hartmann","year":"2016","journal-title":"Schizophrenia research"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2016.04.040","article-title":"Further examination of the reducing transition rate in ultra high risk for psychosis samples: The possible role of earlier intervention","volume":"174","author":"B Nelson","year":"2016","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/schbul\/sbm015","article-title":"Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk?","volume":"33","author":"A R Yung","year":"2007","journal-title":"Schizophr Bull"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/wps.20498","article-title":"Psychosis-risk criteria in the general population: Frequent misinterpretations and current evidence","volume":"17","author":"F Schultze-Lutter","year":"2018","journal-title":"World Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1017\/S0033291717002586","article-title":"Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community","volume":"48","author":"F Schultze-Lutter","year":"2018","journal-title":"Psychol Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial","volume":"67","author":"G P Amminger","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1192\/bjp.185.4.291","article-title":"Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial","volume":"185","author":"A P Morrison","year":"2004","journal-title":"Br J Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1017\/S003329171400244X","article-title":"Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study","volume":"45","author":"P Fusar-Poli","year":"2015","journal-title":"Psychol Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1017\/S0033291719002174","article-title":"Poor functional recovery is better predicted than conversion in studies of outcomes of clinical high risk of psychosis: Insight from SHARP","volume":"50","author":"T Zhang","year":"2020","journal-title":"Psychol Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archpsyc.59.10.921","article-title":"Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms","volume":"59","author":"P D McGorry","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/ajp.2006.163.5.790","article-title":"Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis","volume":"163","author":"T H McGlashan","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/0004867419872248","article-title":"Clinical subtypes that predict conversion to psychosis: A canonical correlation analysis study from the ShangHai At Risk for Psychosis program","volume":"54","author":"T Zhang","year":"2020","journal-title":"Aust NZ J Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/0004867420917449","article-title":"Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis)","volume":"54","author":"T Zhang","year":"2020","journal-title":"Aust NZ J Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.schres.2013.11.039","article-title":"Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study","volume":"152","author":"T Zhang","year":"2014","journal-title":"Schizophr Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2017.06.010","article-title":"Assessing the efficacy of imagery-enhanced cognitive behavioral group therapy for social anxiety disorder: Study protocol for a randomized controlled trial","volume":"60","author":"P M McEvoy","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1176\/appi.ajp.2018.18010036","article-title":"Validating the predictive accuracy of the NAPLS-2 psychosis risk calculator in a clinical high-risk sample from the SHARP (Shanghai At Risk for Psychosis) program","volume":"175","author":"T Zhang","year":"2018","journal-title":"Am J Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2147\/NDT.S85654","article-title":"Interaction of social role functioning and coping in people with recent-onset attenuated psychotic symptoms: A case study of three Chinese women at clinical high risk for psychosis","volume":"11","author":"T Zhang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref23","first-page":"571","article-title":"The Chinese version of the SIPS\/SOPS: A pilot study of reliability and validity","volume":"26","author":"L Zheng","year":"2012","journal-title":"Chinese Mental Health J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/oxfordjournals.schbul.a007040","article-title":"Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability","volume":"29","author":"T J Miller","year":"2003","journal-title":"Schizophr Bull"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2010.11.008","article-title":"The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study","volume":"126","author":"R S Kern","year":"2011","journal-title":"Schizophrenia research"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: Co-norming and standardization","volume":"165","author":"R S Kern","year":"2008","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.psychres.2013.09.023","article-title":"An ecologically valid performance-based social functioning assessment battery for schizophrenia","volume":"210","author":"C Shi","year":"2013","journal-title":"Psychiatry Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: The DDD method","volume":"42","author":"S Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials","volume":"180","author":"Y Hayasaka","year":"2015","journal-title":"J Affect Disord"},{"key":"ref30","volume-title":"The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up","author":"T McGlashan","year":"2010"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/pst.1919","article-title":"Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI\/PSI working group on subgroup analysis","volume":"18","author":"A Dane","year":"2019","journal-title":"Pharm Stat"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/bimj.201500147","article-title":"Exploratory subgroup analysis in clinical trials by model selection","volume":"58","author":"G K Rosenkranz","year":"2016","journal-title":"Biom J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/schbul\/sbx197","article-title":"Negative symptoms in early-onset psychosis and their association with antipsychotic treatment failure","volume":"45","author":"J Downs","year":"2019","journal-title":"Schizophr Bull"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","article-title":"A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic)","volume":"205","author":"O D Howes","year":"2014","journal-title":"Br J Psychiatry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eurpsy.2011.02.015","article-title":"Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment","volume":"27","author":"R Hunter","year":"2012","journal-title":"Eur Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eurpsy.2015.01.013","article-title":"EPA guidance on the early intervention in clinical high risk states of psychoses","volume":"30","author":"S J Schmidt","year":"2015","journal-title":"Eur Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0006-3223(03)00321-4","article-title":"Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome","volume":"54","author":"S W Woods","year":"2003","journal-title":"Biol Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4088\/JCP.08m04979ora","article-title":"Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis","volume":"72","author":"A R Yung","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/2167702618773759","article-title":"Motor clusters reveal differences in risk for psychosis, cognitive functioning, and thalamocortical connectivity: Evidence for vulnerability subtypes","volume":"6","author":"D J Dean","year":"2018","journal-title":"Clin Psychol Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(07)61732-2","article-title":"Can antidepressants prevent psychosis?","volume":"370","author":"P Fusar-Poli","year":"2007","journal-title":"Lancet"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1252-2942.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:35:15Z","timestamp":1610062515000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1252-2942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,7]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1252-2942","relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}